HMG-CoA Reductase



HMG-CoA Reductase (or 3-hydroxy-3-methyl-glutaryl-CoA reductase or HMGR) is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum. It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world. The 1985 Nobel Prize in Physiology or Medicine was awarded to Michael S. Brown and Joseph L. Goldstein, “for their discoveries concerning the regulation of cholesterol metabolism.” Their work on HMGR and LDL elucidated the regulatory complexity of cholesterol synthesis.

Biological Role
HMGR is among the most highly regulated enzymes in the human body. It catalyzes the formation of mevalonic acid, the committed step in the biosynthesis of sterols, most notably cholesterol. This reaction can be seen below where HMG-CoA is reduced by NADPH. Despite the poor reputation cholesterol has in the media, it is a critical component of cellular membranes as it is required to establish proper membrane permeability and fluidity. The mevalonate pathway is also responsible for synthesis of the oxygen transporting heme found in red blood cells.

Structure


General Structure
There are two distinct classes of HMGRs, class I HMGRs, which are only found in eukaryotes and are membrane bound and class II HMGRs, which are found in prokaryotes and are soluble. HMGR contains 8 transmembrane domains that have yet to be successfully crystallized, which anchor the protein to the membrane of the endoplasmic reticulum. The catalytic portion of human HMGR forms a tetramer, with the individual monomers winding around each other. Within the tetramer, the monomers are arranged into two dimers, each of which contains two active sites which are formed by residues form both monomers. Each monomer contains three domains, the N-domain , the L-Domain , and the S-Domain. The L-domain is unique to HMGRs while the S-domain, which forms the binding site for NADP, resembles that of ferredoxin. The S and L domains are connected by a “cis-loop” which is essential for the HMG-binding site. Salt bridges between residues R641 and E782 as well as hydrogen bonds between E700 and E700 on neighboring monomers compliment the largely hydrophobic dimer-dimer interface.

Substrate Binding & Catalytic Mechanism
The HMG-CoA and NADPH molecules make numerous contacts with the L and S domains in forming the four active sites. The CoA is located in a near the enzyme surface, with the pantothenic acid moiety extending into the interior of the protein. Tyrosine 479 forms a hydrophobic lid over the CoA adenine base, shielding the extended binding pocket from solution. The NADPH binding site is formed primarily by the S-domain with a loop region playing a critical role in binding.

The HMG binding pocket is the site of catalysis in HMGR.  The“cis-loop” that bends over the top of HMG (1dqa) is a critical structural element of this binding site. Residues E559 and D767 and are positioned in the active site as is K691 which is only 2.7 angstroms from the HMG O2 carbonyl oxygen. It is this K691 that likely stabilizes the negatively charged oxygen of the first mevaldyl-CoA intermediate. The mevaldyl CoA intermediate is subsequently converted to Mavaldehyde with added stabilization from <scene name='HMG-CoA_Reductase/1dqa_h866/2'>H866, which is within hydrogen bonding distance of the thiol group. It is then believed that the close proximity of <scene name='HMG-CoA_Reductase/1dqa_e_and_d/2'>E559 and D767 increases the pKA of E559, allowing it to be a proton donor for the reduction of mevaldehyde into mevalonate.

Regulation of HMG-CoA Reductase
As stated before, HMGR is among the most highly regulated enzymes in the human body. Regulation of HMG-CoA reductase occurs at 4 different levels of feedback regulation. First by regulation of transcription of the reductase gene, which is activated by sterol regulatory element binding protein, a protein that binds to the promoter of the HMGR gene when cholesterol levels fall. The second level of regulation is at the translation of the HMGR mRNA, which is inhibited by Farnesol, a derivative of the mevalonate pathway.

The third level of HMGR regulation involves the degradation of intact reductase. As the level of sterols increases, HMGR reductase becomes more susceptible to ER-associated degradation. Helices 2-6 of the HMGR transmembrane domain, called the sterol-sensing domain, sense the increased levels of sterols. Degradation of HMGR is initiated when a membrane-bound cysteine protease cleaves residues within the transmembrane region of HMGR. Additionally, as sterol levels increase, the helices can expose Lysine 248 which can be ubiquitinated and subsequently trigger proteolytic degradation.

A final level of HMGR regulation is achieved by inhibition via <scene name='HMG-CoA_Reductase/1dqa_phosphorylation_871/1'>phosphorylation of Serine 872. HMGR is phosphorylated and inactivated by an AMP-activated protein kinase, when the energy charge of the cell is low and AMP concentrations are high. Since Serine 872 is in the vicinity of the pohsphate of NADP, phosphorylation likely results in a decreased affinity for NADPH, halting the formation of Mevaldyl-CoA from HMG-CoA.

</StructureSection>

Medical Implications
<StructureSection load='1aoi' size='500' side='right' scene='HMG-CoA_Reductase/Statin_intro/2' caption='Structure of HMG-CoA Reductase Bound to Statins'>

Medical Implications for HMGR
Elevated cholesterol levels have been identified as a major risk factor for coronary artery disease, the narrowing of arteries of the heart, which affected over 13 million people in the United States alone. It is a major cause of disability and death, killing over 500 thousand people in the USA in 2001.

The statins are HMG-CoA reductase inhibitors. Discovered by Akira Endo in 1971, statins are similar in structure to HMG-CoA and act by competitively inhibiting HMGR. Since HMGR is the first committed enzyme in the cascade that eventually produces cholesterol, use of statins can dramatically reduce blood cholesterol levels. As a drug class, statins generated over $20 billion in sales in 2009 with Pfizer’s Lipitor being the best selling drug in the world at the time of writing. Statin development stands as a triumph for rational drug design validating rational drug design as a proven approach toward creating selective, therapeutic compounds.

A number of crystal structures of HMGR with bound statins have been solved which elucidate how the statin molecule is bound by HMGR. Statins in general occupy the active site of HMGR, preventing HMG-CoA from binding. The structure of HMGR with bound statins (<scene name='HMG-CoA_Reductase/Statin_ator/7'>here atorvastatin, (1hwk) marketed as Lipitor) shows that the cis loop forms a number of polar interactions with the statin inhibitor, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of the statins contribute to binding as well. These interactions result in the statins binding to HMGR with a Ki of between .1-2.3nM while the Michaelis constant KM for HMG-CoA is 4uM, allowing the statins to outcompete HMG-CoA in binding to HMGR. Additional structures of HMGR with the statins <scene name='HMG-CoA_Reductase/Statin_meva/5'>mevastatin (compactin) (1hw8), <scene name='HMG-CoA_Reductase/Statin_simva/5'>simvastatin (1hw9, Zocor), <scene name='HMG-CoA_Reductase/Statin_fluva/6'>fluvastatin (1hwi, Lescol), <scene name='HMG-CoA_Reductase/Statin_ceriv/3'>cerivastatin (1hwj, Baycol), and <scene name='HMG-CoA_Reductase/Statin_rosu/5'>rosuvastatin (1hwl, Crestor) highlight the important residues involved in inhibitor binding. Other statins approved by the FDA include Lovastatin.

</StructureSection>

HGMCR
1r7i - PmHMGCR catalytic domain - Pseudomonas mevalonii 3qae, 3qau - PmHMGCR (mutant) - Streptococcus pneumoniae

HGMCR+statins
3cct, 3ccw, 3ccz, 3cd0, 3cd5, 3cd7, 3cda, 3cdb, 2r4f, 3bgl, 2q1l, 2q6b, 2q6c, 1hw8, 1hw9, 1hwi, 1hwj, 1hwk, 1hwl – HMG-CoA Reductase Catalytic Domain + Statins

1t02 - PmHMGCR catalytic domain + statin derivatives

HGMCR+cofactors
1r31 – PmHMGCR catalytic domain +CoA+mevalonate

1qax - PmHMGCR catalytic domain +HMG+CoA+NAD+

1qay - PmHMGCR catalytic domain +mevalonate+NAD+

1dq8 - hHMGCR catalytic domain (mutant) +CoA+HMG

1dq9 - hHMGCR catalytic domain (mutant)+HMG-CoA

1dqa - hHMGCR catalytic domain (mutant)+HMG+CoA+NADP+

Additional Resources

 * See: Pharmaceutical Drug Targets For Additional Information about Drug Targets for Related Diseases
 * See: Metabolic Disorders For Additional Information.